Company Profiles

driven by the PitchBook Platform

Apitope International

Description

Provider of antigen-specific therapeutic peptides designed to develop novel therapeutics that directly target the underlying cause of allergy and autoimmune disease. The company's peptide therapies are focused pm the treatment of allergy and autoimmune diseases, including multiple sclerosis, Graves' disease and Uveitis, enabling patients to enjoy a normal quality of life without the risk of secondary infection and further complications.

2002

Founded

PRIVATE

Status

11-50

Employees

Series B

Latest Deal Type

$13.5M

Latest Deal Amount

$26.8M

Total Amount Raised

Description

Provider of antigen-specific therapeutic peptides designed to develop novel therapeutics that directly target the underlying cause of allergy and autoimmune disease. The company's peptide therapies are focused pm the treatment of allergy and autoimmune diseases, including multiple sclerosis, Graves' disease and Uveitis, enabling patients to enjoy a normal quality of life without the risk of secondary infection and further complications.

Website:

www.apitope.com

Ownership Status

Privately held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Drug Discovery

Other Industries

Biotechnology

Primary Office

Agoralaan Building A-bis 3590 DiepenbeekBelgium +32 (0)1 128 69 00
Request a free trial to the PitchBook Platform
You're viewing a free company profile from the PitchBook Platform. To explore Apitope International's full profile, request a free trial.

Apitope International Valuation and Funding

Request access
Deal TypeDateAmountRaised to DatePost-ValStatusStage

Apitope International Investors (9)

Request access
Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
Seat
Contact
Info
Arthurian Life SciencesVenture CapitalMinority000 0000000 0000
Limburg InvestmentVenture CapitalMinority000 0000000 0000
National Multiple Sclerosis Society (NMSS)OtherMinority000 0000000 0000
Participatiemaatschappij VlaanderenVenture CapitalMinority000 0000000 0000
University of BristolCorporationMinority000 0000000 0000
Arthurian Life Sciences Venture Capital
Limburg Investment Venture Capital
National Multiple Sclerosis Society (NMSS) Other
Participatiemaatschappij Vlaanderen Venture Capital
University of Bristol Corporation

Apitope International Executive Team (7)

NameTitleBoard
Seat
Contact
Info
Keith Martin Ph.DChief Executive Officer & Board Member
David WraithFounder, Chief Scientific Officer & Board Member
Hayley French Ph.DCommercial Director & General Counsel
Graham Roberts Ph.DDirector, Development
Andrea Jahraus Ph.DDirector, Operations
Keith Martin Ph.D Chief Executive Officer & Board Member
David Wraith Founder, Chief Scientific Officer & Board Member
Hayley French Ph.D Commercial Director & General Counsel
Graham Roberts Ph.D Director, Development
Andrea Jahraus Ph.D Director, Operations

Apitope International Board Members (6)

NameRepresentingRoleSinceContact
Info
Barbara Leyman Ph.DLimburg InvestmentHead of Health and Care000 0000
Brenig PreestArthurian Life SciencesInvestment Director000 0000
Gaston Matthyssens Ph.DVesalius Biocapital PartnersManaging Partner000 0000
Keith Martin Ph.DApitope InternationalChief Executive Officer & Board Member000 0000
Richard DanielsSelfBoard Member000 0000
Barbara Leyman Ph.D Head of Health and Care Limburg Investment
Brenig Preest Investment Director Arthurian Life Sciences
Gaston Matthyssens Ph.D Managing Partner Vesalius Biocapital Partners
Keith Martin Ph.D Chief Executive Officer & Board Member Apitope International
Richard Daniels Board Member Self
Request full access to PitchBook